Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 9

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Authors Lai C, Kandahari AM, Ujjani C

Received 28 September 2019

Accepted for publication 21 November 2019

Published 9 December 2019 Volume 2019:9 Pages 63—71

DOI https://doi.org/10.2147/BLCTT.S231821

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor David Dingli


Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2

1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USA

Correspondence: Catherine Lai
Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA
Tel +1-202-444-3735
Fax +1-202-444-0939
Email Catherine.lai@gunet.georgetown.edu

Abstract: The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.

Keywords: antibody-drug conjugate, brentuximab vedotin, CD30, immunotherapy, classical Hodgkin lymphoma, novel therapies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]